51552-98-8

Basic information

• Product Name: 3-PHENYL-BUTYRYL CHLORIDE
• Synonyms: 3-PHENYL-BUTYRYL CHLORIDE
• CAS NO: 51552-98-8
• Molecular Formula: C₁₀H₁₁ClO
• Molecular Weight: 182.65
• Mol File: 51552-98-8.mol
• Article Data: 27

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-PHENYL-BUTYRYL CHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-PHENYL-BUTYRYL CHLORIDE(51552-98-8)
• EPA Substance Registry System: 3-PHENYL-BUTYRYL CHLORIDE(51552-98-8)

Safety Data

• Hazardous Substances Data: 51552-98-8(Hazardous Substances Data)

Upstream product

• 108-86-1 bromobenzene 
• 79-37-8 oxalyl dichloride 
• 4593-90-2 3-phenylbutyric acid 
• 91970-87-5 (rac)-methyl 3-hydroxy-3-phenylbutanoate 
• 3461-39-0 3-phenyl-butyric acid methyl ester 
• 71-43-2 benzene 
• 98-86-2 acetophenone 

Downstream Products

• 66164-33-8 2,6-diphenyl-4-heptanone 
• 55731-76-5 phenyl-6 methyl-2 heptene-2 one-4 
• 92051-56-4 phenyl-6 methyl-2 chloro-2 heptanone-4 
• 885671-26-1 3-phenyl-butyric acid 4-formyl-2-methoxy-phenyl ester 
• 1148112-13-3 cyclohexanone O-(3-phenylbutanoyl)oxime 
• 1227562-81-3 Fe(C₅H₄CNCH₃OC(O)CH₂CHCH₃C₆H₅)2 
• 861361-52-6 N-(1-methyl-3-oxo-indan-5-yl)benzamide 
• 15074-16-5 1-(2-hydroxyphenyl)-3-phenylbutan-1-one 
• 6072-57-7 3-methylindanone 
• 137585-75-2 3-Phenyl-butyric acid (3aR,5R,6S,6aR)-2,2-dimethyl-5-phenethyl-tetrahydro-furo[2,3-d][1,3]dioxol-6-yl ester 
• 91424-88-3 N,N-Di-sec-butyl-3-phenyl-butyramide 
• 137585-72-9 (S)-3-Phenyl-butyric acid (3aR,5R,6S,6aR)-5-benzyl-2,2-dimethyl-tetrahydro-furo[2,3-d][1,3]dioxol-6-yl ester 
• 133218-34-5 N-(3-Phenylbutyryl)piperidine-2-thione 
• 133218-33-4 N-(3-Phenylbutyryl)pyrrolidine-2-thione 

Relevant articles and documents

TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS

The present disclosure is directed to inhibitors of the CBP/p300 family of bromodomains. The compounds can be useful in the treatment of disease or disorders associated with the inhibition of the CBP/p300 family of bromodomains. For instance, the disclosure is concerned with compounds and compositions for inhibition of the CBP/p300 family of bromodomains, methods of treating, preventing, or ameliorating diseases or disorders associated with the inhibition of CBP/p300 family of bromodomains, and methods of synthesis of these compounds.

Carboxy Group as a Remote and Selective Chelating Group for C?H Activation of Arenes

The first example of carboxy group assisted, remote-selective C(sp2)?H activation with a PdII catalyst has been developed and proceeds through a possible κ2 coordination of the carboxy group, thus suppressing the ortho-C?H activation through κ1 coordination. Besides meta-C?H olefination, direct meta-arylation of hydrocinnamic acid derivatives with low-cost aryl iodides has been achieved for the first time. These findings may motivate the exploration of novel reactivities of the carboxy assisted C?H activation reactions with intriguing selectivities.

3-Phenylalkyl-2H-chromenes and -chromans as novel rhinovirus infection inhibitors

Following our studies on structure-activity relationships of anti-rhinovirus chromene and chroman derivatives, we designed and synthesized new series of 3-phenylalkyl-2H-chromenes and -chromans bearing differently sized, aliphatic linker chains between the two cycles. The cytotoxicity and the antiviral activity of the new compounds on human rhinovirus (HRV) serotype 1B and 14 infection were evaluated in HeLa cell cultures. Most of the tested compounds interfered with HRV1B multiplication in the micromolar or submicromolar concentrations while HRV14 was less susceptible. 3-[3-(4-Chlorophenyl)propyl]chroman (9c) was selected for preliminary mechanism of action studies due to its potent activity against both serotypes (IC50 of 0.48?μM and 1.36?μM towards HRV1B and 14, respectively) coupled with high selectivity (SI?=?206.18 and 73.26, respectively). Results of time of addition/removal studies suggest that 9c, similarly to related derivatives, behaves as a capsid binder interfering with some early events of the HRV1B infectious cycle.